echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > [Latest] Inventory of innovative drugs on the market: it is time to forge ahead

    [Latest] Inventory of innovative drugs on the market: it is time to forge ahead

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In 2021, China's innovative drug industry has been advancing rapidly, the number of approvals for marketing has reached a new high, the coverage of therapeutic areas has been further expanded, a number of innovative traditional Chinese medicine drugs have been approved for marketing, and independent research and development has achieved remarkable resul.


    The number of listings hits an all-time high

    The number of listings hits an all-time high

    After years of policy support and R&D investment, China's pharmaceutical industry has gradually entered a period of innovation and harve.


    Figure 1: The number of innovative drugs approved for marketing in China from 2017 to 2021

    A number of domestic "first" innovative drugs were launched

    A number of domestic "first" innovative drugs were launched

    The first ADC drug in China: As a domestic breakthrough drug, Vidicitumab, which was conditionally approved by Rongchang Bio in June 2021 through the priority review and approval process, made a sensation as the first domestic ADC dr.


    The first ADC drug in China:

    The first CAR-T cell therapy in China: The first CAR-T cell therapy that also caused a sensation in the market also included Fosun Kite's Achilles Injection, which was approved for marketing in June 202 This is the first CAR-T cell therapy approved for marketing in Chi.


    The first CAR-T cell therapy in China:

    The first anti-new coronavirus specific drug in China: the combination therapy of ambivirumab/romisevirumab approved by Tengshengbo in December 2021 is the first fully self-developed and strictly randomized, double-blind, placebo-controlled therapy in Chi.


    The first anti-coronavirus drug in China:

    The first domestically produced PD-L1 monoclonal antibody: Nvolimumab, which was approved for marketing by ThinkConray in November 2021, has sparked a boom in the launch of PD-1/L1, a biological drug target that has been favored in recent yea.


    The first domestic PD-L1 mAb:

    In addition, breakthrough drugs for different indications, such as Anlotinib, Tetacept, Euthydron, and Pilateni, were also released for the first ti.


    Wider coverage of therapeutic areas

    Wider coverage of therapeutic areas

    In 2021, the therapeutic areas of innovative drugs approved for marketing in China will become more extensi.


    Innovative Chinese medicines usher in an outbreak period

    Innovative Chinese medicines usher in an outbreak period

    The domestically approved innovative drugs in 2021 include 7 traditional Chinese medicines and natural medicin.


    Yinqiao Qingre Tablets: Kangyuan Pharmaceutical's Yinqiao Qingre Tablets was developed based on Yinqiao Baidu Decoction, the formula in "Warm and Heat Classic Ji.


    Yinqiao Heat-clearing Tablets:

    Xuanqijiangu Tablets: The holder of the drug marketing authorization is Hunan Fangsheng Pharmaceutical .


    Xuan Qi Jian bone tablets:

    Qizhi Yishen Capsule: The holder of the drug marketing license is Shandong Phoenix Pharmaceutical .


    Qizhi Yishen Capsules:

    Kunxinning Granules: The holder of the drug marketing authorization is Tasly Pharmaceutical Group .


    Kunxinning Granules:

    Huzhen Qingfeng Capsule: The holder of the drug marketing license is Yili Pharmaceutical .


    Huzhen Qingfeng Capsules:

    Jieyu Chufan Capsule: The holder of the drug marketing authorization is Shijiazhuang Yiling Pharmaceutical .


    Jieyu Chufan Capsules:

    Qirui Weishu Capsule: Developed by Jianmin Pharmaceutical, the formula is derived from the in-house preparation of Guang'anmen Hospital, Chinese Academy of Chinese Medical Scienc.


    Qirui Weishu Capsules:

    Independent research and development has entered the harvest period

    Independent research and development has entered the harvest period

    Among the 38 innovative drugs that will be launched in 2021, 34 are self-developed products, accounting for 847%, among which fumetinib, pamiparib, sevolitinib, vedicetumab, and saparibone The six products of Kang and sugelimab have achieved "licence-out", which to a certain extent reflects the strength of China's pharmaceutical innovati.

    Table 1: New Drugs Approved by NMPA in 2021

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.